Novel dissymmetric 3,5-bis(arylidene)-4-piperidones as potential antitumor agents with biological evaluation in vitro and in vivo

Thirty-five novel dissymmetric 3,5-bis(arylidene)-4-piperidone derivatives (BAPs) were generated and evaluated as potential antitumor agents in vitro and in vivo.357